DiaMedica Therapeutics Inc.DMAC

DiaMedica Therapeutics Inc. (DMAC, Nasdaq) is a clinical-stage biopharmaceutical outfit chasing three high-stakes indications with one molecule, DM199 (rinvecalinase), an engineered form of human kallikrein-1 designed to modulate vascular biology and inflammation. The company’s latest 10-Q shows $4.9 million in cash at 31 March 2026, down from $8.1 million at year-end 2025, and a quarterly burn of $9.1 million in operating cash used. Assets of $53.1 million are almost entirely intangibles and prepaid expenses, with $47.2 million of shareholders’ equity providing the only visible cushion against further dilution.

The narrative, however, is running ahead of the balance sheet. DiaMedica’s press site is alive with announcements: first patients dosed in a Phase 2 trial for fetal growth restriction, interim Phase 2 preeclampsia data showing statistically significant blood-pressure reductions and no placental transfer, and a white paper arguing DM199’s potential in fetal growth restriction authored by Professors Stephen Tong, Susan Walker and Catherine Cluver. The company also confirmed it received FDA feedback on the DM199 preeclampsia nonclinical program, stating that a rat reproductive toxicity study may be acceptable to support a U.S. filing-no approvals granted, just regulatory comfort.

Filings show net loss of $10.0 million and operating loss of $10.5 million for Q1 2026, with R&D expense of $8.0 million and less than $10k spent on capex. Cash used in operating activities was $9.1 million, and the company reports $4.9 million in cash and cash equivalents at 31 March 2026. Six insider Form 4 filings on 3 June 2026 record option grants and dispositions, while the board approved inducement grants under Nasdaq Listing Rule 5635(c)(4), a common optics move for listings under pressure.

For context on liquidity and market mechanics, see the EDGAR filing index and submissions JSON for DMAC on SEC EDGAR: https://www.sec.gov/edgar/browse/?CIK=1401040 and https://data.sec.gov/submissions/CIK0001401040.json.

The tension is simple: the science narrative is advancing, but the cash runway is short and the balance sheet is thin. Next evidence to watch is whether FDA feedback converts into a clear path to an IND or CTA for preeclampsia or fetal growth restriction, and whether the fetal growth restriction Phase 2 trial yields data that can support a partnering discussion before the next capital call.